Introduction: To determine if the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in type 2 diabetic mellitus (T2DM) patients affects outcomes after hemiarthroplasty for femoral neck fractures (FNFs). Methods: A retrospective cross-sectional analysis of a local hospital system database was performed using Current Procedural Terminology (CPT) and International Classification of Diseases (ICD-10) codes to identify T2DM patients who were at least 18 years of age who underwent hemiarthroplasty (HA) for FNFs and were on a GLP-1RA at the time of injury. A random patient sample of those who underwent HA and were not on a GLP-1RA was used as a control. Sex, age, body mass index (BMI), smoking status, and Elixhauser comorbidity index (ECI) were control variables. The primary outcomes were initial hospital length of stay (LOS), surgical site infection (SSI) within 90 and 365 days, and medical complications in 30 days. Secondary outcomes were all-cause readmissions within 90 days, implant complications, revision surgery, and in-hospital mortality or discharge to hospice within 365 days. A sub-analysis was performed on patients taking semaglutide, dulaglutide, or liraglutide to those not on GLP-1RA. Results: 499 patients were identified that met study criteria, GLP-1RA use was not significantly associated with an increased risk of medical complication, re-admission within 30 days, hardware failure within 1 year, the likelihood of revision surgery within 1 year, in-hospital mortality/discharge to hospice within 30 days or 1 year, or LOS when controlling for sex, age, BMI, smoking status, and ECI (p>0.5). ECI was associated with increased risk of medical complication, re-admission within 30 days, in-hospital mortality/discharge to hospice within 30 days or 1 year, and LOS (p